$NVAX (-0,36%) | Novavax Q3 '24 Earnings Highlights:
๐น Revenue: $84.5M (Est. $61.3M) ๐ข
๐น Loss per Share: -$0.76 (Est. -$0.77) ๐ข
๐น R&D Expenses: $87.2M (Est. $104.1M) ๐ข
๐น Cash and Cash Equivalents: $573.6M (Est. $530.7M) ๐ข
๐น Product Sales: $38.2M (Est. $69.8M) ๐ด
FY24 Guidance:ย
๐น Total Revenue: $650M - $700M (Prior: $700M - $800M) ๐ด
๐น Product Sales: $175M - $225M (Prior: $275M - $375M) ๐ด
๐น Licensing & Royalties: $475M (up from prior $425M) ๐ข
Key Highlights:ย
๐ธ FDA lifted clinical hold on COVID-19-Influenza Combination vaccine, enabling Phase 3 trials.ย
๐ธ Achieved authorization for updated 2024-2025 COVID-19 vaccine for ages 12+ in the U.S. and EU.ย
๐ธ Partnership with Sanofi on track, with commercial responsibilities for Nuvaxovid to transfer in 2025.
Financial Overview:ย
๐ธ Net Loss: $121M (DOWN from $131M YoY)
๐ธ Significant cost reductions in R&D and SG&A, down 26% YoY in Q3.
CEO Commentary:ย
๐ธ "Focused on strategic growth beyond COVID-19, leveraging partnerships like Sanofi and expanding our proven technology platform."